(Q38092777)

28 August 2017

Synthesis and pharmacology of proteasome inhibitors (English)

1 reference

28 August 2017

1 reference

Andreas Rentsch

1

1 reference

28 August 2017

Dirk Landsberg

2

1 reference

28 August 2017

Tobias Brodmann

3

1 reference

28 August 2017

Leila Bülow

4

1 reference

28 August 2017

Anna-Katharina Girbig

5

1 reference

28 August 2017

Markus Kalesse

6

1 reference

28 August 2017

language of work or name

English

0 references

publication date

25 March 2013

1 reference

Angewandte Chemie International Edition

28 August 2017

0 references

volume

52

1 reference

28 August 2017

21

1 reference

28 August 2017

5450-5488

1 reference

ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation

28 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Not just research tools--proteasome inhibitors offer therapeutic promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Back to the future with ubiquitin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The 26 S proteasome: from basic mechanisms to drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The yeast cell cycle gene CDC34 encodes a ubiquitin-conjugating enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Cyclin is degraded by the ubiquitin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The role of the proteasome in the generation of MHC class I ligands and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Degradation of CFTR by the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The proteasome and proteasome inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The proteasome system: a neglected tool for improvement of novel therapeutic strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Polyubiquitin chains: polymeric protein signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Lingering mysteries of ubiquitin-chain assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Autoregulation of an E2 enzyme by ubiquitin-chain assembly on its catalytic residue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Recognition and processing of ubiquitin-protein conjugates by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The proteasome: paradigm of a self-compartmentalizing protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

20S proteasome and its inhibitors: crystallographic knowledge for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Exploiting nature's rich source of proteasome inhibitors as starting points in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Natural product inhibitors of the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Proteasome inhibitors: an expanding army attacking a unique target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The persisting challenge of selective and specific proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

New polyhydroxy sterols: proteasome inhibitors from a marine sponge Acanthodendrilla sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

7-hydroxy-3-(4-hydroxybenzyl)chroman and broussonin b: neurotrophic compounds, isolated from Anemarrhena asphodeloides BUNGE, function as proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Apigenin, chrysin, and luteolin selectively inhibit chymotrypsin-like and trypsin-like proteasome catalytic activities in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Structure-activity relationships of flavonoid-induced cytotoxicity on human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Inhibition of proteasome activity by anthocyanins and anthocyanidins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

In vitro effects of gliotoxin, a natural proteasome inhibitor, on the infectivity and proteolytic activity of Toxoplasma gondii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Plasmodium falciparum: the fungal metabolite gliotoxin inhibits proteasome proteolytic activity and exerts a plasmodicidal effect on P. falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Chemical proteomics discloses petrosapongiolide M, an antiinflammatory marine sesterterpene, as a proteasome inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Activities of Z-ajoene against tumour and viral spreading in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Mode of action of epoxyphomalins A and B and characterization of related metabolites from the marine-derived fungus Paraconiothyrium sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Aaptamine, an alkaloid from the sponge Aaptos suberitoides, functions as a proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Suberitine A-D, four new cytotoxic dimeric aaptamine alkaloids from the marine sponge Aaptos suberitoides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A meta-analysis on alcohol drinking and gastric cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Hydroxyureas as noncovalent proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Proteasome inhibitors in cancer therapy: lessons from the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Current status of bortezomib in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Bortezomib in the front-line treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The ubiquitin-proteasome pathway and proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Proteasome inhibition by fellutamide B induces nerve growth factor synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Inhibition of proteasome activity by tyropeptin A in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Amide bond formation and peptide coupling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Synthesis of peptide aldehydes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Synthesis of modified peptides with C-terminal alpha-amino aldehydes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Asymmetric copper-catalyzed synthesis of alpha-amino boronate esters from N-tert-butanesulfinyl aldimines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The carmaphycins: new proteasome inhibitors exhibiting an α,β-epoxyketone warhead from a marine cyanobacterium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Fundamental reaction pathway and free energy profile for inhibition of proteasome by Epoxomicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Spirodiepoxides in total synthesis: epoxomicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Spirodiepoxides: synthesis of epoxomicinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Thiopeptide antibiotic biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Antiplasmodial thiostrepton derivatives: proteasome inhibitors with a dual mode of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Three-dimensional structure-activity relationship study of belactosin A and its stereo- and regioisomers: development of potent proteasome inhibitors by a stereochemical diversity-oriented strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Formal synthesis of belactosin A and hormaomycin via a diastereoselective intramolecular cyclopropanation of an alpha-nitro diazoester

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Synthesis and biological activity of optimized belactosin C congeners

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Synthesis and biological activity of simplified belactosin C analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Total synthesis of lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Structural Analysis of Spiro β-Lactone Proteasome Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A simple stereocontrolled synthesis of salinosporamide A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The vinylogous intramolecular Morita-Baylis-Hillman reaction: synthesis of functionalized cyclopentenes and cyclohexenes with trialkylphosphines as nucleophilic catalysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Application of the intramolecular vinylogous Morita-Baylis-Hillman reaction toward the synthesis of the spinosyn A tricyclic nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Correlation between pK(a) and reactivity of quinuclidine-based catalysts in the Baylis-Hillman reaction: discovery of quinuclidine as optimum catalyst leading to substantial enhancement of scope

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The oxidation of the carbon-silicon bond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

An efficient, stereocontrolled synthesis of a potent omuralide-salinosporin hybrid for selective proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Total synthesis of salinosporamide A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Enantioselective total synthesis of (-)-Salinosporamide A (NPI-0052).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Entry to heterocycles based on indium-catalyzed conia-ene reactions: asymmetric synthesis of (-)-salinosporamide A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A concise route to (+)-lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Syntheses and kinetic evaluation of racemic and optically active 2-benzyl-2-methyl-3,4-epoxybutanoic acids as irreversible inactivators for carboxypeptidase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Concise total synthesis of (+/-)-salinosporamide A, (+/-)-cinnabaramide A, and derivatives via a bis-cyclization process: implications for a biosynthetic pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Aqueous phosphoric acid as a mild reagent for deprotection of tert-butyl carbamates, esters, and ethers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Formal synthesis of salinosporamide A via NHC-catalyzed intramolecular lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Concise formal synthesis of (-)-salinosporamide A (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring-opening strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Biosynthetic convergence of salinosporamides A and B in the marine actinomycete Salinispora tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The chemistry and biology of syringolins, glidobactins and cepafungins (syrbactins).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Total synthesis of syringolin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Total synthesis of syringolin A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The total synthesis of proteasome inhibitors TMC-95A and TMC-95B: discovery of a new method to generate cis-propenyl amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Stereocontrolled synthesis of the northern part of potent proteasome inhibitor TMC-95A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

A concise, total synthesis of the TMC-95A/B proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

The core structure of TMC-95A is a promising lead for reversible proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Binding mode of TMC-95A analogues to eukaryotic 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Total synthesis of TMC-95A and -B via a new reaction leading to Z-enamides. Some preliminary findings as to SAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Synthesis of macrocyclic peptide analogues of proteasome inhibitor TMC-95A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Linear TMC-95-based proteasome inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Directed chiral synthesis with pinanediol boronic esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Total Synthesis of the Cyclic Heptapeptide Argyrin B: A New Potent Inhibitor of T-Cell Independent Antibody Formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Cationic Porphyrins Are Reversible Proteasome Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Use of ozonolysis in the synthesis of C-terminal peptide aldehydes on solid support

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201207900

Tyropeptins A and B, New Proteasome Inhibitors Produced by Kitasatospora sp. MK993-dF2. I. Taxonomy, Isolation, Physico-chemical Properties and Biological Activities.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.54.997

Isolation and structural determination of phepropeptins A, B, C, and D, new proteasome inhibitors, produced by Streptomyces sp.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.54.874

TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.53.105

Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.44.117

Isolation of cepafungins I, II and III from Pseudomonas species

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.43.783

Glidobactins D, E, F, G and H; minor components of the antitumor antibiotic glidobactin

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.41.1906

Glidobactins A, B and C, new antitumor antibiotics. II. Structure elucidation.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.41.1338

Glidobactins A, B and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.41.1331

Identifiers

DOI

10.1002/ANIE.201207900

1 reference

28 August 2017

1 reference